FILE PHOTO: A vial and syringe are seen in front of Merck logo in this illustration taken March 26, 2025. REUTERS/Dado Ruvic/Illustration/File Photo FILE PHOTO: A vial and syringe are seen in front of ...

FILE PHOTO: A vial and syringe are seen in front of Merck logo in this illustration taken March 26, 2025. REUTERS/Dado Ruvic/Illustration/File Photo (Reuters) -Merck and Eisai's experimental ...

Merck & Co. and Eisai previously had high hopes for their Keytruda-Lenvima combination in a liver cancer subtype based on positive progression-free survival data, but now the combo’s promise has once ...

The 2025 edition of Time’s annual “best inventions” list saw the magazine expand the docket from 200 to 300 innovations—more than 10% of which comprise medical devices, pharmaceuticals and other novel ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicated subsidiary company to ...

Thermo Fisher to buy clinical services provider Clario for up to $9.4 billion Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, ...

Patients with mild to moderate Alzheimer’s disease can now treat themselves at home with the latest drug for the neurodegenerative disease. In August, the FDA approved the first self-injectable form ...

Ivana Rubino works at Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States. Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey 07677, United States.